Epidemiology of Bacteremia at Two Tertiary ICUs in Switzerland

Bacteremia Clinical Trial

Official title:

Duration of Antimicrobial Treatment for Bloodstream Infections in Swiss Critically Ill Patients - Retrospective Double Center Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05236283
• Other study ID #: 2021-02302
• Status: Completed
• Start date: February 1, 2022
• Est. completion date: March 30, 2022

Study information

• Verified date: January 2023
• Source: University Hospital Inselspital, Berne
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospitals (ICU Inselspital Bern and ICU CHUV Lausanne), to examine patient, pathogen and infectious syndrome factors associated with selection of shortened treatment duration, and to describe the expected time course of clinical resolution among bacteremic patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 395
• Est. completion date: March 30, 2022
• Est. primary completion date: March 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patient has a positive blood culture with a pathogenic organism Patient is critically ill

at the time the blood culture was collected as defined by the following:

1. was treated at the ICU/IMC at the time of blood culture collection;

2. or has been admitted to ICU/IMC in the 48 hours after blood culture collection

Exclusion Criteria:

1. Patient has a single positive blood culture with a common contaminant organism:

• coagulase negative staphylococci;
• Bacillus spp.;
• Corynebacterium spp.;
• Propionibacterium spp.;
• Aerococcus spp.;
• Micrococcus spp.

2. Explicit documentation that the patient does not want to participate in any study

Related Conditions & MeSH terms

• Bacteremia

Intervention

Diagnostic Test:
• Blood Culture
Blood Culture

Locations

Country	Name	City	State
Switzerland	Departement of Intensive Care Medicine	Bern

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antibiotic Treatment Duration	Days of adequate antibiotic treatment in Patients with Bacteremia	Hospital discharge, expected to be on average ca. 15-20 days
Secondary	Days of ICU stay	Days of ICU Stay in Patients with Bacteremia	ICU discharge, expected to be on average ca. 5-15 days
Secondary	Days of hospital stay	Days of Inhospital Stay in Patients with Bacteremia	Hospital discharge, expected to be on average ca. 15-25 days